Source:

Press Release

November 22, 2020
2 min read
Save

Inaugural class of FDA-AACR oncology educational fellows announced

Source:

Press Release

You've successfully added to your alerts. You will receive an email when new content is published.

Click Here to Manage Email Alerts

We were unable to process your request. Please try again later. If you continue to have this issue please contact customerservice@slackinc.com.

American Association for Cancer Research announced the 2020-2021 class of FDA-AACR oncology educational fellows.

The FDA-AACR oncology educational fellowship — a joint effort of AACR and FDA’s Oncology Center of Excellence — is intended to promote scientific progress through research, collaborative learning and education.

 The main entrance of FDA Building 1.
Source: US FDA.

The fellows will gain experience and become familiar with oncology drug development and the regulatory review process through interaction with experts and targeted educational activities.

Richard Pazdur
Richard Pazdur

“It’s our great pleasure to help enrich the education of other physicians and open lines of communication with oncology professionals about the FDA’s work in drug development,” Richard Pazdur, MD, director of FDA’s Oncology Center of Excellence, said in a press release. “We hope this program will provide a window on what we do and how we think at the FDA.”

The 20 fellows in this inaugural class took part in a competitive application process. All are hematology/oncology fellows and early-career cancer investigators at cancer centers in the United States or Canada.

Margaret Foti
Margaret Foti

“This exciting project will provide 20 talented young researchers and physician-scientists with a unique opportunity to more fully appreciate how regulatory science informs the way in which new cancer medicines are evaluated for their safety and efficacy,” Margaret Foti, PhD, MD (hc), CEO of AACR, said in the release.

The 2020-2021 fellows are:

  • Samer Al Hadidi, MD, of Baylor College of Medicine;
  • Gagandeep Brar, MD, of Weill Cornell Medicine and NewYork-Presbyterian;
  • Michael Burns, MD, PhD, of Northwestern University;
  • Chris Chen, MD, of Stanford University;
  • Izak Faiena, MD, of Columbia University Medical Center;
  • Parvaneh Fallah, MD, of McGill University;
  • Aparna Hegde, MD, of The University of Alabama at Birmingham O’Neal Comprehensive Cancer Center;
  • Henry J. Henderson III, PhD, of Vanderbilt University Medical Center;
  • Jasmine Huynh, MD, of University of California Davis Comprehensive Cancer Center;
  • Ana Rosa Sáez Ibáñez, PhD, of Albert Einstein College of Medicine/Icahn School of Medicine at Mount Sinai;
  • Yasmin Kadry, PhD, of University of Pennsylvania;
  • Justin Lo, MD, PhD, of Vanderbilt University Medical Center;
  • Lin Mei, MD, of Charleston Area Medical Center;
  • Ryan Nguyen, DO, of University of Illinois at Chicago;
  • Timil Patel, MD, of Yale University School of Medicine;
  • Jacqulyne Robichaux, PhD, of The University of Texas MD Anderson Cancer Center;
  • Ilana Schlam, MD, of MedStar Georgetown Washington Hospital Center;
  • Misty Dawn Shields, MD, PhD, of Moffitt Cancer Center;
  • Jasmine Sukumar, MD, of The Ohio State University Comprehensive Cancer Center; and
  • Neil Vasan, MD, PhD, of Memorial Sloan Kettering Cancer Center.